Nova Biomedical Acquires NanoCellect Assets to Expand Cell Line Development Portfolio

Nova Biomedical acquired certain assets of NanoCellect, which develops microfluidic cell sorting technology, to expand its capabilities in cell line development and strengthen support for biopharmaceutical workflows from early research through commercial manufacturing.

The acquisition adds NanoCellect’s WOLF G2^® cell sorting platform to Nova’s biopharma portfolio. The microfluidic-based technology enables gentle cell selection and isolation and complements Nova’s Solentim platform for clone generation, verification, and growth analysis, according to Nova Biomedical. Together, the technologies provide a more integrated workflow spanning cell selection, single-cell isolation, and clone verification.

By combining these capabilities, Nova aims to accelerate cell line development, improve clone selection, and create a stronger foundation for downstream process development, scale-up, and manufacturing.

The expanded portfolio also integrates with Nova’s existing analytical technologies for cell culture monitoring, including the BioProfile^® FLEX2 metabolite analyzer, OsmoTECH^® osmolality measurement systems, and the BioProfile^® FAST CDV cell counting and viability analyzer. These instruments provide critical process data throughout bioprocess development and manufacturing.

According to the company, the addition of NanoCellect’s technology advances its strategy of offering a connected portfolio of tools that support continuity, data-driven decision-making, and process optimization across the entire bioprocessing lifecycle.

“NanoCellect adds a critical upstream capability to our portfolio and strengthens our ability to connect key steps in cell line development,” said John Luck, president of Nova Biomedical’s Biopharma Business. “By integrating cell sorting with clone isolation and high-confidence verification, alongside analytical control points such as cell culture monitoring and osmolality, we are enabling customers to reach a successful clone more quickly and generate insights that help optimize clone selection and drive better performance during process development, scaleup, and manufacturing.

“This is an important step in building a more connected and differentiated platform for cell line development and bioprocessing.”

The post Nova Biomedical Acquires NanoCellect Assets to Expand Cell Line Development Portfolio appeared first on GEN - Genetic Engineering and Biotechnology News.